[AF] WHO Pharmaceuticals Newsletter No. 4, 2006

[Martín Cañás]

Estimadas y estimados
 
Está disponible el  WHO Pharmaceuticals  Newsletter No. 4, 2006
con el siguiente índice
 
 
Regulatory  Matters
 
ADHD  Drugs --  Labelling revised
Cimicifuga racemosa (Black  Cohosh) --  Concerns of liver injury 1
Fluoxetine --  Use extended to include paediatric patients  1
Natalizumab --  Reintroduced under Restricted Distribution/Risk Management Plan  2
SSRIs --  Challenges in pregnancy  2
SSRIs  and SNRIs --  Combined use with anti-migraine medicines could be life-threatening  3
Telithromycin --  New safety information in label  3
Tipranavir --  Reports of intracranial haemorrhage 3
Triaminic  Vapour Patch --  Risk of ingestion  4
Venlafaxine --  Information update to minimize overdose-side effects  4

Safety of  Medicines
 
Angiotensin-converting  enzyme (ACE) inhibitors --  Risk of birth defects  5
Chemotherapy/Immunosuppressive  therapy --  Reactivation of hepatitis B virus infection  5
Colchicine --  Toxic in overdose: reminder  5
Colloids --  Safety considerations important in choosing resuscitation fluids  6
Dolasetron  mesylate --  Contraindicated in patients below 18 years of age; not for use in  post-operative
nausea and vomiting  6
Gadodiamide --  Reports of nephrogenic systemic fibrosis  6
Nitrofurantoin --  Reports of interstitial lung disease 7
Proton  pump inhibitors --  Update on reports of interstitial nephritis  7
Sibutramine --  ADR update from ADRAC  7
SSRIs  and tricyclic antidepressants (TCAs) --  Potential for interaction  7
 
Feature
 
WHO Consultation on Global Monitoring of Adverse Events  Following Immunization (AEFI) 
9-10 January 2006: A Report9
 

La direccion es:
http://www.who.int/medicines/publications/newsletter/pn2006_4.pdf 
 
Saludos,
 
Martín Cañás
GAPURMED
(Argentina)
macanas en netverk.com.ar